Publication of Annual Report and Accounts Delayed

Suspension of Shares

29 December 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that due to delays in completing the audit for the year ended 30 June 2022, it will not publish its annual report and accounts by 31 December 2022. Consequently, the shares of the Company will be suspended from trading from 7.30am on 3 January 2023.

The Company announced its unaudited preliminary results on 29 September 2022, and it is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts.

As previously announced, the Company is actively reviewing all funding options following the voluntary pause in production that has led to the need for significant additional near-term funding. The Company is in active discussions on funding and will update the market in due course.

For further information on the Company, please visit the website: www.allergytherapeutics.com.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

-  ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which employs c.600 employees, is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.